Wegovy and Mounjaro are prescription medicines that clinicians may use as part of a medical weight management plan. In the UK, these medicines are not for casual or cosmetic weight loss and should only be used after a proper clinical assessment and only when they are safe and suitable for the patient.
Both treatments work alongside lifestyle changes such as healthier eating and increased physical activity, rather than replacing them. Instead, they may help some people control appetite and stay on track with a structured weight management plan.
Although both medicines affect appetite and blood sugar pathways, they are not the same. They contain different active ingredients and act on different hormone targets. Understanding the difference between Wegovy and Mounjaro can help patients ask better questions during a consultation and understand why one option may suit them better than another.
If you want confidential support from a regulated provider, NewGen Pharmacy’s online consultation service explains how assessment and follow-up may work in practice.
What Is Wegovy?
Wegovy contains semaglutide. Semaglutide belongs to a group of medicines called GLP-1 receptor agonists. In simple terms, it copies the action of the natural GLP-1 hormone, which helps control appetite and food intake.
This may help by:
- reducing hunger
- slowing stomach emptying
- helping some people feel fuller for longer after meals
Wegovy is usually given as a once-weekly injection. In the UK, clinicians use it for weight management in adults with obesity, or in some adults living with a higher body weight and weight-related health problems, alongside a reduced-calorie diet and increased physical activity.
Patients should not assume that online discussion means the medicine will be right for them. A clinician still needs to check medical history, current health, and treatment goals before deciding whether Wegovy is appropriate.
What Is Mounjaro?
Mounjaro contains tirzepatide. Tirzepatide works in a different way from semaglutide because it acts on more than one hormone pathway. It targets both GLP-1 and GIP receptors.
These pathways help control:
- appetite
- blood sugar balance
- energy use
Like Wegovy, Mounjaro is usually taken as a once-weekly injection after a clinical assessment. It may help some people feel fuller for longer and less hungry. However, it is still only one part of a wider weight management plan.
As with Wegovy, a clinician must decide whether Mounjaro is suitable. Suitability depends on factors such as BMI, weight-related conditions, medical history, and possible risks.
Main Differences Between Wegovy and Mounjaro
Although both medicines support weight management, they work in different ways.
| Feature | Wegovy | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Hormone targets | GLP-1 | GLP-1 and GIP |
| Dosing | Weekly injection | Weekly injection |
| Role in treatment | Weight management support | Weight management support |
The main difference is the hormone pathway. Wegovy works on GLP-1 only. Mounjaro works on both GLP-1 and GIP. That does not mean one medicine is always better than the other. A prescriber must look at the full clinical picture before recommending treatment.
That picture may include:
- medical history
- current health
- BMI
- weight-related conditions
- side-effect risk
- previous weight management efforts
- patient preference
Patients should also remember that NHS access and private prescribing are not the same. NHS treatment depends on national guidance and local service rules. Private prescribing still requires a safe, lawful, and patient-specific assessment.
If you want to learn more about the support available, you can visit the NewGen Pharmacy homepage.
Who May Be Eligible for Treatment?
In the UK, clinicians may consider weight management medicines for adults with obesity, or for adults living with a higher body weight plus weight-related health conditions, when lifestyle changes alone have not been enough.
Broadly, treatment may be considered for adults who:
- have a BMI of 30 or above, or
- have a BMI of 27 or above with a weight-related health condition
In the NHS, eligibility for treatment is usually narrower than the general product licence and follows formal NICE recommendations.
Weight-related conditions may include:
- high blood pressure
- type 2 diabetes
- sleep apnoea
- cardiovascular risk factors
However, eligibility is not based on BMI alone. A clinician also needs to review medical history, current medicines, pregnancy status, and any reasons why treatment may not be suitable.
This is why proper assessment matters so much. Two people may have the same BMI but very different treatment needs.
Possible Side Effects
Like all medicines, Wegovy and Mounjaro can cause side effects. Many of the common side effects affect the digestive system.
Examples may include:
- nausea
- vomiting
- diarrhoea
- constipation
- stomach discomfort
- reduced appetite
The type and strength of side effects can vary from person to person. Some patients get mild symptoms that settle with time. Others may find symptoms harder to manage, especially when the dose increases.
Patients should seek advice if they develop severe stomach pain, repeated vomiting, dehydration, or other symptoms that feel worrying or unusual. They should also follow the dosing plan carefully and ask for advice if they miss a dose or struggle with side effects.
When to Seek Advice
If you are finding weight management difficult despite efforts with diet and exercise, it may help to speak to a healthcare professional rather than trying to choose a medicine yourself.
A clinician can:
- review your medical history
- assess your current health
- explain whether treatment may be appropriate
- discuss benefits and risks
- help you understand the safest next steps
You should also seek advice if you have:
- strong or ongoing side effects
- a history of pancreatitis
- complex medical conditions
- questions about pregnancy, breastfeeding, or contraception
- concerns about whether treatment is right for you
Weight management treatment should always start with proper clinical review, not self-selection.
How NewGen Can Help
NewGen Pharmacy understands that weight management concerns can feel personal and frustrating. Our team offers confidential, judgement-free advice about medical weight management and healthy lifestyle support. We can explain how assessments work, what eligibility may involve, and what a treatment plan may look like.
Our pharmacists and clinicians can also:
- help you understand the difference between Wegovy and Mounjaro
- explain how weekly injection treatments are used after prescribing, where clinically appropriate
- talk through lifestyle changes that support healthy weight management
- direct you to appropriate local or online services for treatment and ongoing support
If you want to take the next step, you can use these links:
Book your consultation: https://newgenpharmacy.co.uk/book-a-consultation/
Read more about weight management support: https://newgenpharmacy.co.uk/newgen-pharmacy-weight-management-treatment/
Learn how online consultations work: https://newgenpharmacy.co.uk/online-consultations/
Frequently Asked Questions
Is Wegovy the same as Mounjaro?
No. Wegovy contains semaglutide and works on GLP-1 receptors. Mounjaro contains tirzepatide and works on both GLP-1 and GIP receptors.
Are Wegovy and Mounjaro both weekly injections?
Yes. Clinicians usually prescribe both as once-weekly injections after a proper assessment.
Can I get these medicines just because I want to lose a small amount of weight?
These medicines are not for casual or cosmetic weight loss. A clinician should only prescribe them when there is a clear medical reason and when treatment is safe and suitable.
Does NHS eligibility differ from private prescribing?
Yes. NHS access depends on national guidance and local service rules. Private prescribing still requires a full clinical assessment and lawful prescribing.
What side effects are common with Wegovy and Mounjaro?
Common side effects often include nausea, vomiting, constipation, diarrhoea, and stomach discomfort. Patients should seek advice if symptoms are severe or do not settle.
Compliance note: We do not promote prescription-only medicines publicly in a promotional way. A clinician only discusses treatment options privately after an appropriate assessment and only where this is safe, lawful, and suitable.
Author & Content Writer: Dr Naeem Aslam
